Related Experiment Video
Updated: Aug 10, 2025
Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles
Published on: November 1, 2017
Studies of the Antitumor Activity of Iodacetate in the Liposomal Form
D A Korshunov1, M A Buldakov2, E E Sereda2,3
1Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia. ieved@ya.ru.
Abstract:
Metabolic reprogramming has become the new hallmark of cancer. Carbohydrate metabolism is a key component of metabolic transformations in tumors. To date, many therapeutic agents have been identified that target proteins and enzymes involved in glucose transport and metabolism, with promising results in cell culture studies and animal tumor models. In our studies, we found that the most promising among them is the glycolysis inhibitor iodoacetate. The study of this agent showed that iodoacetate in liposomal form has the best performance. With a course introduction, its antimetastatic and antitumor activity reached significant indices of growth inhibition. At the same time, liposomes with iodoacetate had an almost completely safe toxicological profile compared to the independent form and, as a result, have great potential in polychemotherapy.
Insights
Liposomal iodoacetate shows significant antitumor and antimetastatic activity by inhibiting glycolysis. This formulation demonstrates a favorable safety profile, indicating potential for cancer polychemotherapy.
Area of Science:
- Oncology
- Cancer Metabolism
- Drug Delivery
Background:
- Metabolic reprogramming is a hallmark of cancer, with carbohydrate metabolism playing a crucial role.
- Targeting glucose metabolism is a promising therapeutic strategy for cancer treatment.
- Iodoacetate is a known glycolysis inhibitor with potential anticancer properties.
Purpose of the Study:
- To evaluate the efficacy and safety of liposomal iodoacetate as an anticancer agent.
- To investigate the antimetastatic and antitumor activity of iodoacetate delivered via liposomes.
- To assess the toxicological profile of liposomal iodoacetate compared to free iodoacetate.
Main Methods:
- In vitro and in vivo studies using cell cultures and animal tumor models.
- Administration of iodoacetate in both free and liposomal formulations.
- Assessment of tumor growth inhibition, metastatic spread, and toxicological parameters.
Main Results:
- Liposomal iodoacetate exhibited significant antitumor and antimetastatic activity.
- The liposomal formulation demonstrated superior efficacy compared to free iodoacetate.
- Liposomal iodoacetate presented an improved safety profile with reduced toxicity.
Conclusions:
- Liposomal iodoacetate is a promising therapeutic agent for cancer treatment.
- The liposomal delivery system enhances the efficacy and safety of iodoacetate.
- This formulation holds potential for integration into polychemotherapy regimens.
